Brief: Neovacs Continues To Develop IFNα Kinoid With CKD Pharmaceuticals

Neovacs SA

11/10/2018 06:10

Oct 11 (Reuters) - NEOVACS SA  ALNEV.PA :
    * REG-NEOVACS ANNOUNCES THE CONTINUATION OF THE DEVELOPMENT
OF ITS
IFNALPHA KINOID IN SOUTH KOREA WITH ITS PARTNER CHONG KUN DANG
(CKD) PHARMACEUTICALS
    * SAYS WILL RECEIVE POTENTIALLY UP TO 5 MILLION EUROS IN
TOTAL
UNDER THIS LICENSE AGREEMENT IN SEQUENCED PAYMENTS
    * PAYMENTS TO BE BASED ON ACHIEVEMENT OF CERTAIN MILESTONES,
WHICH
INCLUDE PHASE IIB RESULTS
    * AGREEMENT COVERS DEVELOPMENT AND COMMERCIALIZATION OF
IFNALPHA
KINOID IN SOUTH KOREA FOR LUPUS AND DERMATOMYOSITIS INDICATIONS

Source text: https://bit.ly/2EdGfm2
Further company coverage:  ALNEV.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))